Annual report pursuant to Section 13 and 15(d)

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.23.4
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
$ in Thousands
 12 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Segment Reporting Information [Line Items]    
Net income (loss) $ (9,930) $ (13,771)
Total operating costs and expenses 11,221 13,875
Less non-cash share-based compensation (4,735) (6,655)
Operating costs and expenses excluding non-cash share based compensation 6,486 7,220
Total assets 25,522 30,412
CAR-T Therapeutics [Member]    
Segment Reporting Information [Line Items]    
Net income (loss) (3,879) (5,776)
Operating costs and expenses excluding non-cash share based compensation 2,467 3,206
Total assets 7,523 16,921
Cancer Vaccines [Member]    
Segment Reporting Information [Line Items]    
Net income (loss) (5,111) (4,889)
Operating costs and expenses excluding non-cash share based compensation 3,265 2,355
Total assets 17,215 9,442
Anti-Viral Therapeutics [Member]    
Segment Reporting Information [Line Items]    
Net income (loss) (945) (3,075)
Operating costs and expenses excluding non-cash share based compensation 553 1,634
Total assets 700 3,811
Other [Member]    
Segment Reporting Information [Line Items]    
Net income (loss) 5 (31)
Operating costs and expenses excluding non-cash share based compensation 201 25
Total assets $ 84 $ 238